Adherex Technologies is planning to move its common stock share listing to a U.S.-based exchange as part of its corporation relocation to RTP from Canada, William Peters, chairman and CEO, said on Thursday.

Adherex shares are likely to end up on the American stock exchange, he said. Its stock is now traded on the Toronto exchange.

Adherex, which recently received approval from the FDA to begin clinical trials for its anti-tumor drug Exherin, has four anti-cancer drugs in development.

It has 17 employees, 12 of whom are already in Durham.